Skip To Content

Study ID: Genentech Hoffmann La Roche WO39210

Title:

A PHASE III, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH PD-L1-SELECTED RENAL CELL CARCINOMA AT INTERMEDIATE TO HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY

Location:
Sioux Falls Region
Principal Investigator:
Christopher Sumey, MD
Disease:
REN (Renal)
Stage:
Phase III
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.